The historical data trend for Lipocine's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2VT0 vs NCEL, PTN, ALLR: Buyback Yield % Comparison
For the Biotechnology subindustry, Lipocine's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipocine Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipocine's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Lipocine's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipocine (STU:2VT0) has a Buyback Yield % of -75.28 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lipocine and its competitors. According to the industry distribution chart, Lipocine ranks #656 out of 741 companies in the Biotechnology industry, placing it in the top 88.5%.
Is Lipocine's Buyback Yield % too high?
Lipocine's current Buyback Yield % is -75.28. Based on the distribution chart, Lipocine ranks #656 out of 741 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lipocine has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's Buyback Yield % compare to NCEL and PTN?
According to the Biotechnology industry distribution chart, Lipocine ranks #656 out of 741 companies for Buyback Yield %. This places Lipocine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lipocine and its competitors. Lipocine's current Buyback Yield % is -75.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current Buyback Yield % of -75.28. The stock's GF Value™ is €3.10, compared to a current price of €3.94 — trading 27.2% above its estimated fair value. The current Buyback Yield % is -75.28. Lipocine's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current Buyback Yield % is -75.28 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lipocine (STU:2VT0) Overvalued in 2026?
Based on GuruFocus' analysis, Lipocine stock appears to be overvalued.
The current stock price of €3.94 is trading 27.2% above its estimated GF Value™ of €3.10.
Key valuation signals for STU:2VT0:
Buyback Yield %: -75.28
GF Value™: €3.10 vs. price of €3.94 (27.2% above fair value)
No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
52GF Score
Get the complete analysis for STU:2VT0
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2VT0 has been successfully added to your 
